Advanced Cell Technology

Advanced Cell Technology

Advanced Cell Technology is the previous name of Octa Therapeutics, which is now called Astellas Institute for Regenerative Medicine. The biotechnology company is a subsidiary of Astellas Pharma and was initially focused on the development of regenerative opthalmology therapeutics using stem cells.

All edits

Edits on 16 Feb, 2021
Golden AI"prospector:150:82578"
Golden AI edited on 16 Feb, 2021
Edits made to:
Infobox (+4 properties)
Infobox
Legal name
Advanced Cell Technology Inc.
Industry
Pharmaceuticals Industry
Stock symbol
ACTC
Edits on 28 Sep, 2020
Holden Page
Holden Page edited on 28 Sep, 2020
Edits made to:
Article (+714/-713 characters)
Article

In 2014 Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. and Ocata Therapeutics became a subsidiary of Astellas. In 2018 the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE.

...

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE. In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).

In 2014, Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. and Ocata Therapeutics became a subsidiary of Astellas. In 2018 the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).

Edits on 22 Sep, 2020
Erin Scherfner
Erin Scherfner approved a suggestion from Golden's AI on 22 Sep, 2020
Edits made to:
Article (+11/-11 characters)
Article

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE. In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South KoreaSouth Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).

Edits on 22 Sep, 2020
Meredith Hanel
Meredith Hanel edited on 22 Sep, 2020
Edits made to:
Article (+647 characters)
Article

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE. In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).

Meredith Hanel
Meredith Hanel edited on 22 Sep, 2020
Edits made to:
Description (+111/-26 characters)
Article (+97 characters)
Topic thumbnail

Advanced Cell Technology

Advanced Cell Technology is the previous name of Octa Therapeutics, which is now called OcataAstellas Therapuetics,Institute isfor aRegenerative Medicine. The biotechnology company that is a subsidiary of Astellas Pharma and was initially focused on the development of regenerative opthalmology therapeutics using stem cells.

Article

In 2014 Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. and Ocata Therapeutics became a subsidiary of Astellas. In 2018 the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).

Meredith Hanel
Meredith Hanel edited on 22 Sep, 2020
Edits made to:
Infobox (+1 properties)
Description (+44 characters)
Article (+260 characters)
Topic thumbnail

Advanced Cell Technology

Advanced Cell Technology, now called Ocata Therapuetics, is a biotechnology company that is a subsidiary of Astellas Pharma and focused on the development of regenerative opthalmology therapeutics using stem cells.

Article

In 2014 Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. Ocata Therapeutics became a subsidiary of Astellas.

Infobox
Location
Boston
Edits on 10 Jul, 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 10 Jul, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 14 Mar, 2019
Dawson Sewell
Dawson Sewell edited on 14 Mar, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Healthcare
Dawson Sewell
Dawson Sewell edited on 14 Mar, 2019
Edits made to:
Infobox (+2 properties)
Description (+94/-1 characters)
Further reading (+1 rows) (+4 cells) (+174 characters)
Categories (+2/-2 topics)
Related Topics (+2 topics)
Topic thumbnail

Advanced Cell Technology

AAdvanced Cell Technology, now called Ocata Therapuetics, is a biotechnology company focused on the development of regenerative opthalmology therapeutics using stem cells.

Further reading

Title
Author
Link
Type

Advanced Cell Technology Changes Name to Ocata Therapeutics

BusinessWire

Web

Infobox
Industry
Stem cell
Categories
Related Topics
Edits on 4 Feb, 2019
Golden AI"Import data"
Golden AI edited on 4 Feb, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Biotechnology
Edits on 9 Jan, 2019
Golden AI
Golden AI edited on 9 Jan, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Is a
Company
Edits on 12 Dec, 2018
Golden AI"Import data"
Golden AI edited on 12 Dec, 2018
Edits made to:
Infobox (+3 properties)
People (+4 rows) (+8 cells) (+80 characters)
Categories (+1 topics)
People

Name
Role
Related Golden topics

Adel Bakhtiarova

Employee

David Levy

Employee

David Levy

Investor

Jeffrey Long

Employee

Infobox
Market
Biotechnology
Categories
Edits on 29 Jun, 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun, 2018
Infobox
Edits on 18 Jun, 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun, 2018
Edits made to:
Description (+78/-21 characters)
Topic thumbnail

Advanced Cell Technology

Biotechnology company

A company focused on the development of regenerative opthalmology therapeutics

Edits on 29 May, 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May, 2018
Edits made to:
Description (+21 characters)
Categories (+1 topics)
Topic thumbnail

 Advanced Cell Technology

Biotechnology company

Categories
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.